Search results for "cough"

showing 10 items of 101 documents

Recurrent respiratory infections caused by a double aortic arch: The diagnostic role of spirometry

2013

AbstractA young woman with a clinical history characterized by recurrent respiratory infections, occurring since early infancy, was referred to our hospital. When the patient was a young girl, she underwent sweat chloride test, serum analysis of immunoglobulins, and evaluation of blood lymphocyte subsets; all these diagnostic tests were normal, as well as chest X ray aside from pneumonia episodes. Skin prick tests were positive for several different allergens, and a diagnosis of allergic rhinitis was made. At the age of 11 years, she started to complain of gastroesophageal reflux disease (GERD) symptoms, and a gastroscopy detected a hiatal hernia with esophagitis. Despite pharmacologic trea…

Pulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyDouble aortic archmedicine.diagnostic_testbusiness.industryspirometryCase Reportdouble aortic arch; respiratory infections; spirometrydouble aortic archGastro-esophageal reflux symptomsmedicine.diseasePulmonary function testingSurgeryHiatal herniarespiratory infectionsChronic coughPneumoniamedicineGERDCentral airway obstructionmedicine.symptombusinessVascular ringsEsophagitisRespiratory Medicine Case Reports
researchProduct

Alternative mechanisms for tiotropium

2009

Tiotropium is commonly used in the treatment of chronic obstructive pulmonary disease. Although largely considered to be a long-acting bronchodilator, its demonstrated efficacy in reducing the frequency of exacerbations and preliminary evidence from early studies indicating that it might slow the rate of decline in lung function suggested mechanisms of action in addition to simple bronchodilation. This hypothesis was examined in the recently published UPLIFT study and, although spirometric and other clinical benefits of tiotropium treatment extended to four years, the rate of decline in lung function did not appear to be reduced by the addition of tiotropium in this study. This article summ…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyANTICHOLINERGIC BRONCHODILATORmedicine.drug_classRespiratory SystemScopolamine DerivativesPulmonary diseaseIPRATROPIUM BROMIDEIpratropium bromideOBSTRUCTIVE PULMONARY-DISEASEMUCOCILIARY CLEARANCECholinergic AntagonistsRECEPTORS MEDIATE STIMULATIONParasympathetic Nervous SystemAIRWAY SMOOTH-MUSCLEBronchodilatorBronchodilationMechanismsBRONCHIAL EPITHELIAL-CELLSAnimalsHumansMedicineCOPDPharmacology (medical)Tiotropium BromideIntensive care medicineLungLung functionInflammationCOPDbusiness.industryTiotropiumBiochemistry (medical)RemodellingTiotropium bromidemedicine.diseaseAcetylcholineBronchodilator Agentsrespiratory tract diseasesMucusClinical researchNONNEURONAL CHOLINERGIC SYSTEMCoughPOLYSPECIFIC CATION TRANSPORTERSAnesthesiaLUNG FIBROBLAST PROLIFERATIONbusinesshuman activitiesmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Advances in Pulmonary Medicine: Research and Innovations

2019

This book discusses a wide range of investigations and practice-oriented advances in pulmonary medicine and critical care. Pulmonary diseases are a major cause of hospitalization and mortality, affecting millions of people worldwide. Addressing a range of topics, including chronic obstructive pulmonary disease, sleep apnea, and lung cancer, the book offers insights into the disease mechanisms and risk factors, along with practical aspects concerning the maintenance of quality of life, adherence to therapy, and palliative treatment and care. Further, it explores diagnostic and treatment approaches to respiratory dysfunction and respiratory failure, highlighting the beneficial effects of good…

Quality of lifeCoughSleep disordered breathingChronic obstructive pulmonary diseaseRespiratory physiotherapyCancer researchPulmonary infections
researchProduct

PB3. Pharyngeal Electrical Stimulation in neurointensive care patients suffering from severe post-stroke dysphagia – Post stimulation increase of sal…

2018

Introduction Dysphagia is one of the most important and prognostically relevant complications of acute stroke. Pharyngeal Electrical Stimulation (PES) is a treatment device that enhances cortical reorganization for the restoration of swallowing function after cerebral injury. Furthermore, it was shown that PES leads to a temporary increase of Substance P (SP) level in saliva but not serum in healthy adults. The neuropeptide SP likely acts as a neurotransmitter in the pharyngeal mucosa and enhances the swallow and cough reflex. Post-stroke dysphagia may be related to reduced SP-levels. Here, we investigated the association of PES treatment in neurointensive care patients suffering from sever…

Salivabusiness.industrymedicine.medical_treatmentCough reflexNeurointensive careStimulationDysphagiaSensory SystemsTracheotomyNeurologySwallowingPhysiology (medical)AnesthesiamedicineBiomarker (medicine)Neurology (clinical)medicine.symptombusinessClinical Neurophysiology
researchProduct

Interleukin-6 Is a Promising Marker of COVID-19 in Children: A Case Series of 2 Brothers with Severe COVID-19 Pneumonia.

2022

BACKGROUND To date, Coronavirus disease 2019 (COVID-19) remains a global health concern, with fatalities mostly in older age groups with underlying medical conditions, while children are less likely to manifest severe symptoms. CASE REPORT We describe the clinical cases of 2 brothers admitted to our Children's Hospital for persistent fever and cough during the COVID-19 pandemic. Case 1. A 1.5-year-old boy had fever, expiratory dyspnea, desaturation, oxygen saturation 94-96% with O2, and bilateral hissing and crackling rales. His interleukin-6 level in the acute phase of the disease was 100.41 and at the resolution it was 46.2 pg/ml. Treatment with amoxicillin plus clavulanic acid, methylpre…

Settore MED/04 - Patologia GeneraleMaleFeverInterleukin-6SARS-CoV-2SiblingsCOVID-19InfantGeneral MedicinePneumoniaMethylprednisoloneSettore MED/38 - Pediatria Generale E SpecialisticaCoughHumansPandemicsAgedThe American journal of case reports
researchProduct

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georg…

2009

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consen…

Settore MED/07 - Microbiologia E Microbiologia ClinicaBordetella pertussisStandardizationVaccine evaluationU.S.HarmonizationMedical and Health SciencesArticleBordetella pertussisPertussis vaccinesVirologyHumansMedicineCenters for Disease Control and PreventionWhooping coughLicensureGovernmentMedical educationWhooping coughAgricultural and Veterinary SciencesGeneral VeterinaryGeneral Immunology and MicrobiologybiologyClinical Laboratory Techniquesbusiness.industryPublic Health Environmental and Occupational HealthStandardization of serologic assaysBiological Sciencesbiology.organism_classificationmedicine.diseaseUnited StatesAtlantaInfectious DiseasesImmunologyBordetella pertussis Whooping cough Standardization of serologic assays ELISA Pertussis vaccinesMolecular MedicineELISAbusinessVaccine
researchProduct

Airway obstruction in relation to symptoms in chronic respiratory disease—a nationally representative population study

2000

Abstract We examined the severity of airway obstruction and the occurrence of respiratory symptoms in a large, nationally representative population sample and in a subgroup of subjects with chronic bronchitis and/or emphysema to obtain information for developing national prevention and treatment strategies for these diseases. The study population comprised of 7217 randomly selected subjects (aged 30 years and older) who participated in a comprehensive health examination survey. The ‘cases' were subjects diagnosed as having chronic bronchitis and/or emphysema. The survey methods comprised of questionnaires, interviews, physical measurements, including spirometry, and clinical examinations. I…

SpirometryAdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyChronic bronchitissymptoms.chronic obstructive pulmonary diseaseFEV1/FVC ratioInternal medicineForced Expiratory VolumeSurveys and QuestionnairesOdds RatioPrevalenceMedicineHumansLung Diseases ObstructiveBronchitisFinlandAgedEmphysemamedicine.diagnostic_testbusiness.industryPhlegmRespiratory diseaseSmokinglung functionAirway obstructionMiddle Agedrespiratory systemmedicine.diseaseobstructionrespiratory tract diseasesCold TemperatureChronic coughDyspneaPopulation SurveillanceChronic DiseasePhysical therapyPopulation studychronic bronchitisFemalemedicine.symptombusinessRespiratory Medicine
researchProduct

IMMUNOGENICITY OF AN ACELLULAR PERTUSSIS VACCINE COMPOSED OF GENETICALLY INACTIVATED PERTUSSIS TOXIN COMBINED WITH FILAMENTOUS HEMAGGLUTININ AND PERT…

1993

We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.

Time FactorsFilamentous haemagglutinin adhesinPertussis toxincomplex mixturesBordetella pertussisMicrobiologyNeutralization TestsHumansMedicineVirulence Factors BordetellaAdhesins BacterialImmunization ScheduleWhooping coughPertussis VaccineAntigens Bacterialbusiness.industryImmunogenicitypertussisAntibody titerInfantmedicine.diseaseAntibodies BacterialVirologyVaccinationTiterHemagglutininsPertussis ToxinVaccines InactivatedChild PreschoolImmunoglobulin GPediatrics Perinatology and Child HealthDrug EvaluationPertactinbusinessVaccinepertussis; VaccineBacterial Outer Membrane Proteins
researchProduct

Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety an…

1995

Objective: To evaluate the safety and the immunogenicity of a booster dose of recombinant acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP, Biocine SpA) in 15- to 21-month-old children primed in infancy with either whole-cell diphtheria-tetanus-pertussis (DTwP) vaccine or DTaP vaccine. Design: Open-label second phase of a double-masked, controlled trail, with masked analysis of serum samples. Participants and setting: Three hundred fifty children, 15 to 21 months of age, who had been primed at 2, 4, and 6 months of age with either three doses of DTaP vaccine (n = 173) or DTwP vaccine (n = 177). The children were enrolled in eight vaccination centers in Italy. I…

Time FactorsWhooping CoughImmunization SecondaryEnzyme-Linked Immunosorbent AssayBooster dosecomplex mixturesBordetella pertussisDouble-Blind MethodmedicineHumansVirulence Factors BordetellaDiphtheria-Tetanus-Pertussis VaccineWhooping coughPertussis VaccineVaccines SyntheticTetanusbusiness.industryDiphtheriaToxoidAntibody titerInfantmedicine.diseaseAntibodies BacterialVirologyVACCINE pertussisVaccinationPertussis ToxinPediatrics Perinatology and Child HealthImmunologyPertussis vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct

Booster vaccination after neonatal priming with acellular pertussis vaccine.

2010

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/ Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Whooping CoughFilamentous haemagglutinin adhesinImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesVirusPolio vaccineVaccines AcellularmedicineHumansWhooping coughHepatitis B virusPertussis VaccineDose-Response Relationship Drugbusiness.industryDiphtheriaVaccinationInfant Newbornvirus diseasesInfantmedicine.diseasePrognosisVirologyVaccinationPediatrics Perinatology and Child HealthImmunologybusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct